CY1111471T1 - Μεθοδοι για τον καθαρισμο trans-(-)-δ9-τετραϋδροκανναβινολης και trans-(+)-δ9 τετραϋδροκανναβινολης - Google Patents

Μεθοδοι για τον καθαρισμο trans-(-)-δ9-τετραϋδροκανναβινολης και trans-(+)-δ9 τετραϋδροκανναβινολης

Info

Publication number
CY1111471T1
CY1111471T1 CY20111100473T CY111100473T CY1111471T1 CY 1111471 T1 CY1111471 T1 CY 1111471T1 CY 20111100473 T CY20111100473 T CY 20111100473T CY 111100473 T CY111100473 T CY 111100473T CY 1111471 T1 CY1111471 T1 CY 1111471T1
Authority
CY
Cyprus
Prior art keywords
tetrahydrocannabinol
trans
methods
composition
cleaning
Prior art date
Application number
CY20111100473T
Other languages
English (en)
Inventor
Arie L Gutman
Gennady A Nisnevich
Igor Rukhman
Boris Tishin
Marina Etinger
Irina Fedotev
Boris Pertsikov
Ram Khanolkar
Original Assignee
Euro-Celtique S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35789123&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1111471(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Euro-Celtique S.A. filed Critical Euro-Celtique S.A.
Publication of CY1111471T1 publication Critical patent/CY1111471T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4875—Compounds of unknown constitution, e.g. material from plants or animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/78—Ring systems having three or more relevant rings
    • C07D311/80—Dibenzopyrans; Hydrogenated dibenzopyrans

Abstract

Εδώ περιγράφονται μέθοδοι για την παρασκευή trans-(-)-Δ9-τετραϋδροκανναβινόλης και trans-(+)-Δ9-τετραϋδροκανναβινόλης. Σε μια ενσωμάτωση, μια σύνθεση trans-(-)-Δ9-τετραϋδροκανναβινόλης παρασκευάζεται επιτρέποντας σε μια σύνθεση που περιέχει (±)-Δ9-τετραϋδροκανναβινόλη να διαχωριστεί σε μια χειρόμορφη στατική φάση για την παροχή μιας σύνθεσης trans-(-)-Δ9-τετραϋδροκανναβινόλης που περιέχει τουλάχιστον περίπου 99% κατά βάρος trans-(-)-Δ9-τετραϋδροκανναβινόλη με βάση τη συνολική ποσότητα trans-(-)-Δ9-τετραϋδροκανναβινόλης και trans-(+)-Δ9-τετραϋδροκανναβινόλης. Η εφεύρεση αναφέρεται επίσης σε μεθόδους για τη θεραπεία ή πρόληψη μιας κατάστασης όπως άλγος οι οποίες μέθοδοι περιλαμβάνουν τη χορήγηση σε έναν ασθενή που χρήζει αυτής μιας αποτελεσματικής ποσότητας από μια trans-(-)-Δ9-τετραϋδροκανναβινόλη έχουσα καθαρότητα τουλάχιστον περίπου 98% με βάση το συνολικό βάρος κανναβινοειδών.
CY20111100473T 2004-11-22 2011-05-17 Μεθοδοι για τον καθαρισμο trans-(-)-δ9-τετραϋδροκανναβινολης και trans-(+)-δ9 τετραϋδροκανναβινολης CY1111471T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US63055604P 2004-11-22 2004-11-22
EP05807597A EP1824475B1 (en) 2004-11-22 2005-11-18 Methods for purifying trans-(-)-delta9-tetrahydrocannabinol and trans-(+)-delta9-tetrahydrocannabinol

Publications (1)

Publication Number Publication Date
CY1111471T1 true CY1111471T1 (el) 2015-08-05

Family

ID=35789123

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20111100473T CY1111471T1 (el) 2004-11-22 2011-05-17 Μεθοδοι για τον καθαρισμο trans-(-)-δ9-τετραϋδροκανναβινολης και trans-(+)-δ9 τετραϋδροκανναβινολης

Country Status (31)

Country Link
US (6) US8383842B2 (el)
EP (3) EP2289509B1 (el)
JP (3) JP4995728B2 (el)
KR (1) KR100919719B1 (el)
CN (2) CN102151259A (el)
AR (1) AR054989A1 (el)
AT (1) ATE500824T1 (el)
AU (2) AU2005305944B2 (el)
BR (1) BRPI0519803A2 (el)
CA (2) CA2921590C (el)
CY (1) CY1111471T1 (el)
DE (1) DE602005026852D1 (el)
DK (3) DK2289509T3 (el)
EA (1) EA012299B1 (el)
ES (3) ES2556802T3 (el)
HK (3) HK1109058A1 (el)
HR (3) HRP20110385T1 (el)
HU (2) HUE025904T2 (el)
IL (1) IL183306A (el)
ME (2) ME02306B (el)
MX (1) MX2007006104A (el)
NO (1) NO331831B1 (el)
NZ (1) NZ556038A (el)
PL (3) PL2289509T3 (el)
PT (2) PT2289509E (el)
RS (3) RS54338B1 (el)
SI (3) SI2289509T1 (el)
TW (2) TWI369203B (el)
UA (1) UA88491C2 (el)
WO (1) WO2006053766A1 (el)
ZA (1) ZA200706837B (el)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI369203B (en) 2004-11-22 2012-08-01 Euro Celtique Sa Methods for purifying trans-(-)-△9-tetrahydrocannabinol and trans-(+)-△9-tetrahydrocannabinol
TWI366460B (en) * 2005-06-16 2012-06-21 Euro Celtique Sa Cannabinoid active pharmaceutical ingredient for improved dosage forms
CN101316832A (zh) 2005-09-29 2008-12-03 Amr科技公司 δ-9-四氢***酚的生成方法
US8039509B2 (en) 2006-11-10 2011-10-18 Johnson Matthey Public Limited Company Composition comprising (−)-Δ9-trans-tetrahydrocannabinol
US8980940B2 (en) 2006-11-10 2015-03-17 Johnson Matthey Public Limited Company Stable cannabinoid compositions and methods for making and storing them
GB0702895D0 (en) * 2007-02-14 2007-03-28 Resolution Chemicals Ltd Delta 9 tetrahydrocannabinol derivatives
GB0703284D0 (en) * 2007-02-20 2007-03-28 Resolution Chemicals Ltd Delta 9 - tetrahydrocannabinol processing
CA2751741C (en) * 2008-02-06 2018-07-10 Mallinckrodt Inc. Process for the preparation of (-) -delta 9-tetrahydrocannabinol
US10624859B2 (en) 2012-08-20 2020-04-21 Rhodes Technologies Systems and methods for increasing stability of dronabinol compositions
US10610512B2 (en) 2014-06-26 2020-04-07 Island Breeze Systems Ca, Llc MDI related products and methods of use
US10155708B2 (en) * 2015-01-22 2018-12-18 Phytoplant Research S.L. Methods of purifying cannabinoids, compositions and kits thereof
US11034639B2 (en) 2015-01-22 2021-06-15 Phytoplant Research S.L. Methods of purifying cannabinoids using liquid:liquid chromatography
US10207198B2 (en) 2015-01-22 2019-02-19 Phytoplant Research S.L. Methods of purifying cannabinoids using liquid:liquid chromatography
CN106268657A (zh) * 2015-05-14 2017-01-04 株式会社大赛璐 光学异构体用分离剂
US10059683B2 (en) * 2015-07-10 2018-08-28 Noramco, Inc. Process for the production of cannabidiol and delta-9-tetrahydrocannabinol
CN109153661B (zh) * 2016-05-13 2023-01-17 西姆莱斯有限公司 用于纯化***素化合物的方法
US10499584B2 (en) 2016-05-27 2019-12-10 New West Genetics Industrial hemp Cannabis cultivars and seeds with stable cannabinoid profiles
US10399920B2 (en) 2016-06-01 2019-09-03 S&B Pharma, Inc. Crystalline form of cannabidiol
US10239808B1 (en) 2016-12-07 2019-03-26 Canopy Holdings, LLC Cannabis extracts
CN106810426B (zh) * 2016-12-29 2020-05-08 暨明医药科技（苏州）有限公司 一种***二酚的合成方法
US11213558B2 (en) 2017-05-17 2022-01-04 Orochem Technologies, Inc. CBX extraction-isolation process
US10189762B1 (en) * 2017-07-07 2019-01-29 Orochem Technologies, Inc. Process for purification and separation of cannabinoids, from dried hemp and cannabis leaves
EP3676238A1 (en) * 2017-09-01 2020-07-08 Pureform Global, Inc. Synthetic cannabidiol compositions and methods of making the same
WO2019152736A1 (en) 2018-01-31 2019-08-08 Canopy Holdings, LLC Hemp powder
US11192870B2 (en) 2018-03-07 2021-12-07 Socati Technologies—Oregon, Llc Continuous isolation of cannabidiol and conversion of cannabidiol to delta 8-tetrahydrocannabinol and delta 9-tetrahydrocannabinol
CN112105606A (zh) * 2018-03-07 2020-12-18 索卡蒂科技俄勒冈有限公司 ***素的连续分离以及***素向δ8-四氢***酚和δ9-四氢***酚的转化
US11851415B2 (en) 2018-03-07 2023-12-26 Cleen Technology Inc. Continuous isolation of cannabidiol and cannabinoids and conversion of cannabidiol to delta 8-tetrahydrocannabinol and delta 9-tetrahydrocannabinol
EP3814315A1 (en) * 2018-06-28 2021-05-05 Symrise AG Synthesis of (+)-cannabinoids and their therapeutic effects
CA3073093A1 (en) 2018-08-03 2020-02-06 Biomass Oil Separation Solutions, Llc Processes and apparatus for extraction of substances and enriched extracts from plant material
US11040932B2 (en) 2018-10-10 2021-06-22 Treehouse Biotech, Inc. Synthesis of cannabigerol
US20210380514A1 (en) 2018-10-31 2021-12-09 Enantia S.L. Solid compositions of cocrystals of cannabinoids
EP3653596A1 (en) 2018-11-14 2020-05-20 Indena S.p.A. Continuous flow synthesis of cannabidiol
CN109734554B (zh) * 2019-02-25 2021-11-23 江苏暨明医药科技有限公司 一种反式-薄荷基-2,8-二烯-1-醇的合成工艺
CN111943813B (zh) * 2019-05-17 2023-04-14 上海特化医药科技有限公司 ***二酚类化合物的制备方法
WO2020248062A1 (en) * 2019-06-11 2020-12-17 Canopy Growth Corporation Improved methods for cannabinoid isomerization
US10799546B1 (en) 2019-07-26 2020-10-13 Biomass Oil Separation Solutions, Llc Modular, integrated process and apparatus for extracting, refining and remediating active substances from plant material
US11542243B1 (en) 2019-09-26 2023-01-03 FusionFarms, LLC Method of converting delta9-THC to delta10-THC and the purification of the delta10-THC by crystallization
WO2021081138A1 (en) * 2019-10-21 2021-04-29 Esolate Ltd Compositions comprising superfine compounds and production thereof
GB2588457B (en) * 2019-10-25 2022-12-21 Gw Res Ltd Cannabinoid compound
GB2588455B (en) * 2019-10-25 2022-12-21 Gw Res Ltd Cannabinoid compound
US20220340507A1 (en) 2020-03-12 2022-10-27 Council Of Scientific And Industrial Research An Indian Registered Body Incorporated Under The Regn. Process for the synthesis of cannabidiol and intermediates thereof
CN113336705B (zh) * 2021-08-09 2021-12-10 中国农业科学院农产品加工研究所 一种***二酚-2-咪唑-1-甲酸酯及其应用
WO2024028516A1 (en) 2022-08-05 2024-02-08 Salud & Semillas, S.L. CANNABINOID SYNTHESIS STARTING OUT FROM OLIVETOL AND TERPENE IN DICHLOROMETHANE WITH FeCl3 * 6H2O AS CATALYST
CN115583933B (zh) * 2022-10-31 2024-02-06 暨明医药科技（苏州）有限公司 一种高纯度四氢***素同系物的制备方法
CN115784836A (zh) * 2022-12-08 2023-03-14 南京康立瑞生物科技有限公司 一种高选择性的制备反式-薄荷基-2,8-二烯-1-醇的方法

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3507885A (en) 1966-03-25 1970-04-21 Hoffmann La Roche 3-alkyl-6h-dibenzo(b,d)pyrans
CH481911A (de) 1967-05-19 1969-11-30 Theodor Dr Petrzilka Verfahren zur Herstellung von tricyclischen Verbindungen
US3854480A (en) 1969-04-01 1974-12-17 Alza Corp Drug-delivery system
US3668224A (en) 1970-07-02 1972-06-06 Theodor Petrzilka PROCESS OF PRODUCING 6a, 10a-TRANS-6a,7,8,10a-TETRAHYDRODIBENZO (b,d)-PYRANS
US4025516A (en) 1975-06-23 1977-05-24 The John C. Sheehan Institute For Research, Inc. Process for the preparation of (-)-6a,10a-trans-6a,7,8,10a-tetrahydrodibenzo[b,d]-pyrans
US4381399A (en) 1981-12-21 1983-04-26 Aerojet-General Corporation Purification of tetrahydrodibenzo[b,d]pyrans from crude synthetic mixtures
US4970075A (en) 1986-07-18 1990-11-13 Euroceltique, S.A. Controlled release bases for pharmaceuticals
US4861598A (en) 1986-07-18 1989-08-29 Euroceltique, S.A. Controlled release bases for pharmaceuticals
DE4100441A1 (de) 1991-01-09 1992-07-16 Mack Chem Pharm Verfahren zur herstellung von 6,12-dihydro-6-hydroxy-cannabidiol und dessen verwendung zur herstellung von trans-delta-9-tetrahydrocannabinol
US6703418B2 (en) 1991-02-26 2004-03-09 Unimed Pharmaceuticals, Inc. Appetite stimulation and induction of weight gain in patients suffering from symptomatic HIV infection
US5389375A (en) 1993-05-21 1995-02-14 University Of Mississippi Stable suppository formulations effecting bioavailability of Δ9 -thc
US5965161A (en) 1994-11-04 1999-10-12 Euro-Celtique, S.A. Extruded multi-particulates
AU6111796A (en) 1995-06-12 1997-01-09 G.D. Searle & Co. Compositions comprising a cyclooxygenase-2 inhibitor and a 5 -lipoxygenase inhibitor
US6017963A (en) 1995-11-14 2000-01-25 Euro-Celtique, S.A. Formulation for intranasal administration
US6328992B1 (en) 1997-03-03 2001-12-11 Lawrence L. Brooke Cannabinoid patch and method for cannabis transdermal delivery
GB9726916D0 (en) 1997-12-19 1998-02-18 Danbiosyst Uk Nasal formulation
US6730519B2 (en) 1998-10-26 2004-05-04 The University Of Mississippi Method of preparing delta-9-tetrahydrocannabinol
US20020039795A1 (en) 1998-10-26 2002-04-04 Elsohly Et Al Method of preparing delta-9-tetrahydrocannabinol
US6509005B1 (en) 1998-10-27 2003-01-21 Virginia Commonwealth University Δ9 Tetrahydrocannabinol (Δ9 THC) solution metered dose inhaler
FI990915A0 (fi) 1999-04-23 1999-04-23 Orion Yhtymae Oyj Jauheinhalaattori
US6403126B1 (en) 1999-05-26 2002-06-11 Websar Innovations Inc. Cannabinoid extraction method
US6555139B2 (en) 1999-06-28 2003-04-29 Wockhardt Europe Limited Preparation of micron-size pharmaceutical particles by microfluidization
US6747058B1 (en) 1999-08-20 2004-06-08 Unimed Pharmaceuticals, Inc. Stable composition for inhalation therapy comprising delta-9-tetrahydrocannabinol and semiaqueous solvent therefor
US6620351B2 (en) 2000-05-24 2003-09-16 Auburn University Method of forming nanoparticles and microparticles of controllable size using supercritical fluids with enhanced mass transfer
GB2368061B (en) 2000-10-20 2005-05-11 Gw Pharmaceuticals Ltd Dose dispensing apparatus
KR100968128B1 (ko) 2000-10-30 2010-07-06 유로-셀티크 소시에떼 아노뉨 서방성 하이드로코돈 제형
US6730330B2 (en) 2001-02-14 2004-05-04 Gw Pharma Limited Pharmaceutical formulations
CH695661A5 (de) 2001-03-06 2006-07-31 Forsch Hiscia Ver Fuer Krebsfo Pharmazeutische Zusammensetzung.
EP1409473A2 (en) 2001-03-07 2004-04-21 Websar Innovations Inc. CONVERSION OF CBD TO $g(D)?8 -THC AND $g(D)?9 -THC
US20030050334A1 (en) 2001-04-30 2003-03-13 Murty Ram B. Process for extraction of Delta-9-Tetrahydrocannabinol and other related cannabinoids and preparation of specific strength marijuana cigarettes
GB0112752D0 (en) 2001-05-25 2001-07-18 Johnson Matthey Plc Synthesis of cannabinoids
US20030044458A1 (en) 2001-08-06 2003-03-06 Curtis Wright Oral dosage form comprising a therapeutic agent and an adverse-effect agent
CN100999513A (zh) * 2002-02-01 2007-07-18 分析化学品有限公司 △9四氢***酚的制备
WO2003070506A1 (fr) 2002-02-21 2003-08-28 Biel Timothee Dispositif d'entraînement pour vehicules a moteur, notamment avec propulsion hybride
UA79281C2 (en) 2002-04-03 2007-06-11 Solvay Pharm Bv Stabilized composition comprising a natural cannabinoid compound and process for the preparation thereof
US6946150B2 (en) 2002-08-14 2005-09-20 Gw Pharma Limited Pharmaceutical formulation
GB0222077D0 (en) 2002-09-23 2002-10-30 Gw Pharma Ltd Methods of preparing cannabinoids from plant material
CA2770448C (en) 2002-11-12 2014-03-25 Prairie Plant Systems Inc. Cannabinoid esters
US20040229939A1 (en) 2003-02-14 2004-11-18 Chowdhury Dipak K. Tetrahydrocannabinol compositions and methods of manufacture and use thereof
EP1696929A4 (en) 2003-11-05 2010-02-24 Unimed Pharmaceuticals Inc DELTA-9-THC COMPOSITIONS AND METHODS OF TREATING MULTIPLE SCLEROSIS-RELATED SYMPTOMS
GB0329635D0 (en) * 2003-12-23 2004-01-28 Johnson Matthey Plc Process for purifying trans-tetrahydrocannabinol
EP1773801A1 (de) 2004-07-19 2007-04-18 Cilag Ltd. Verfahren zur gewinnung von reinem tetrahydrocannabinol
GB0425445D0 (en) 2004-11-18 2004-12-22 Smithkline Beecham Corp Novel compositions
TWI369203B (en) * 2004-11-22 2012-08-01 Euro Celtique Sa Methods for purifying trans-(-)-△9-tetrahydrocannabinol and trans-(+)-△9-tetrahydrocannabinol
TWI366460B (en) 2005-06-16 2012-06-21 Euro Celtique Sa Cannabinoid active pharmaceutical ingredient for improved dosage forms
PT2176208E (pt) 2007-07-30 2015-05-11 Zynerba Pharmaceuticals Inc Pró-fármacos de canabidiol, composições compreendendo pró- fármacos de canabidiol e métodos de utilização dos mesmos
US8642645B2 (en) * 2011-05-20 2014-02-04 Brooks Kelly Research, LLC. Pharmaceutical composition comprising Cannabinoids

Also Published As

Publication number Publication date
HUE027197T2 (en) 2016-10-28
DE602005026852D1 (de) 2011-04-21
PL2356987T3 (pl) 2016-09-30
HRP20151301T1 (hr) 2016-01-01
IL183306A0 (en) 2007-09-20
NZ556038A (en) 2009-12-24
CN101076329B (zh) 2011-08-10
EP2356987A1 (en) 2011-08-17
DK1824475T3 (da) 2011-06-06
AU2005305944A1 (en) 2006-05-26
TW201302722A (zh) 2013-01-16
HK1109058A1 (en) 2008-05-30
ME02403B (me) 2016-09-20
EA200701123A1 (ru) 2007-12-28
CA2921590A1 (en) 2006-05-26
SI2356987T1 (sl) 2016-04-29
US20150126596A1 (en) 2015-05-07
KR100919719B1 (ko) 2009-10-06
EP2289509A2 (en) 2011-03-02
RS54338B1 (en) 2016-02-29
US8383842B2 (en) 2013-02-26
US20090298930A1 (en) 2009-12-03
BRPI0519803A2 (pt) 2009-03-17
CA2587957A1 (en) 2006-05-26
US9744151B2 (en) 2017-08-29
UA88491C2 (ru) 2009-10-26
TWI369203B (en) 2012-08-01
AU2010200227A1 (en) 2010-02-11
EP2289509B1 (en) 2015-10-14
US20130171259A1 (en) 2013-07-04
EP1824475B1 (en) 2011-03-09
CA2921590C (en) 2019-09-24
US20160184261A1 (en) 2016-06-30
US9278083B2 (en) 2016-03-08
PL2289509T3 (pl) 2016-04-29
TW200633695A (en) 2006-10-01
PL1824475T3 (pl) 2011-09-30
CN102151259A (zh) 2011-08-17
SI2289509T1 (sl) 2016-01-29
ES2362288T3 (es) 2011-06-30
JP4995728B2 (ja) 2012-08-08
US20160199344A1 (en) 2016-07-14
NO331831B1 (no) 2012-04-16
JP2008101000A (ja) 2008-05-01
EP2356987B1 (en) 2016-01-06
PT1824475E (pt) 2011-06-01
AU2005305944B2 (en) 2010-03-04
ATE500824T1 (de) 2011-03-15
JP2008520608A (ja) 2008-06-19
HK1154796A1 (en) 2012-05-04
ME02306B (me) 2016-06-20
HUE025904T2 (en) 2016-05-30
SI1824475T1 (sl) 2011-06-30
MX2007006104A (es) 2007-07-11
WO2006053766A1 (en) 2006-05-26
CA2587957C (en) 2016-05-03
HRP20160300T1 (hr) 2016-04-22
ZA200706837B (en) 2008-04-30
JP5048448B2 (ja) 2012-10-17
NO20072964L (no) 2007-08-17
RS54537B1 (en) 2016-06-30
TWI436991B (zh) 2014-05-11
DK2356987T3 (en) 2016-03-21
JP2012180350A (ja) 2012-09-20
DK2289509T3 (en) 2015-11-23
US9675581B2 (en) 2017-06-13
WO2006053766A8 (en) 2006-12-14
CN101076329A (zh) 2007-11-21
ES2566480T3 (es) 2016-04-13
HRP20110385T1 (hr) 2011-06-30
EP2289509A3 (en) 2011-08-10
PT2289509E (pt) 2015-12-23
KR20070086529A (ko) 2007-08-27
IL183306A (en) 2012-06-28
HK1159500A1 (en) 2012-08-03
AR054989A1 (es) 2007-08-01
EA012299B1 (ru) 2009-08-28
EP1824475A1 (en) 2007-08-29
US20160184260A1 (en) 2016-06-30
US8937097B2 (en) 2015-01-20
RS51706B (en) 2011-10-31
ES2556802T3 (es) 2016-01-20

Similar Documents

Publication Publication Date Title
CY1111471T1 (el) Μεθοδοι για τον καθαρισμο trans-(-)-δ9-τετραϋδροκανναβινολης και trans-(+)-δ9 τετραϋδροκανναβινολης
CY1111446T1 (el) Συνθεσεις περιλαμβανουσες κρυσταλλικη trans- (+/-)-δελτα-9-τετραϋδροκανναβινολη
CY1106679T1 (el) Αζαδικυκλικες ετεροκυκλικες ενωσεις ως τροποποιητες κανναβινοειδους υποδοχεα
CY1115870T1 (el) Ενωσεις 1,2,4-οξαδιαζολο βενζοϊκου οξεος και χρηση αυτων για μη νοηματικη καταστολη και τη θεραπεια ασθενειας
CY1118148T1 (el) Συνθεση που περιεχει ενωσεις τεταρτοταγους αμμωνιου
CY1115719T1 (el) Νεοι φαρμακευτικοι συνδυασμοι για τη θεραπεια νοσων των αναπνευστικων οδων
CY1105922T1 (el) Χρηση υποκατεστημενων παραγωγων αζετιδινονης στη θepαπεια ασθενειας alzheimer
BRPI0408784A (pt) método para usar um composto
EA201170969A1 (ru) Новые макроциклические ингибиторы репликации вируса гепатита с
CY1115117T1 (el) Παραγωγα υποκατεστημενων οξαζολιδινονων και η χρηση τους ως αναστολεις παραγοντα χα
ECSP10010310A (es) Nuevos compuestos y composiciones y métodos de uso
NI200600290A (es) Derivados de pirazol, composiciones que contienen dichos compuestos y procedimientos de uso
TN2009000180A1 (en) NOVEL 1,4-BENZOTHIEPIN-l,1-DIOXIDE DERIVATIVES WHICH ARE SUBSTITUTED WITH BENZYL GROUPS, METHOD FOR PRODUCING DRUGS CONTAINING SAID COMPOUNDS AND USE THEREOF
CY1113963T1 (el) Φαρμακευτικες συνθεσεις οι οποιες περιλαμβανουν ανταγωνιστες ακτιβινης-actriia και χρηση αυτων στην προληψη η' θεραπευτικη αγωγη πολλαπλου μυελωματος
UY28369A1 (es) Agentes terapéuticos
ATE472551T1 (de) Tocopherolmodifizierte therapeutische arzneimittelverbindung
CY1115690T1 (el) Συνθεσεις βασιζομενες σε arthrospirα και χρησεις αυτων
ECSP067054A (es) Nuevos derivados fluoroglicosídicos de pirazoles, medicamentos que contienen estos compuestos, y el empleo de los mismos
CY1106386T1 (el) Υποκατεστημενα παραγωγα 3-πυρρολιδιν-ινδολης
BRPI0414565A (pt) composições farmacêuticas e métodos que compreendem combinações de derivados de 2-alquilideno-19-nor-vitamina d e um bisfosfonato
BRPI0412851A (pt) benzamidazóis de n-metila-substituìdos
CY1108018T1 (el) Μεθοδος και φαρμακευτικο σκευασμα για την αντιμετωπιση της αντιστασης στα αντιυπερτασικα φαρμακα και για σχετικες παθησεις
SE0402925D0 (sv) Novel Compounds
AR043253A1 (es) 4-[(2,4-dicloro-5-metoxifenil)amino] -6- alcoxi-3-quinolina carbonitrilos para el tratamiento de lesiones isquemicas
BRPI0407968A (pt) derivados de oxamida úteis como inibidores de raf-quinase